Westfield Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $60.9M | Sell |
186,905
-5,267
| -3% | -$1.72M | 0.26% | 120 |
|
|
2025
Q1 | $51.9M | Sell |
192,172
-23,954
| -11% | -$6.47M | 0.25% | 124 |
|
|
2024
Q4 | $50.9M | Buy |
+216,126
| New | +$50.9M | 0.22% | 136 |
|
|
2020
Q2 | – | Sell |
-138,664
| Closed | -$15.1M | – | 231 |
|
|
2020
Q1 | $15.1M | Sell |
138,664
-110,345
| -44% | -$12M | 0.13% | 160 |
|
|
2019
Q4 | $28.7M | Sell |
249,009
-31,288
| -11% | -$3.6M | 0.2% | 137 |
|
|
2019
Q3 | $22.5M | Sell |
280,297
-155,736
| -36% | -$12.5M | 0.18% | 147 |
|
|
2019
Q2 | $31.6M | Buy |
436,033
+116,110
| +36% | +$8.43M | 0.24% | 136 |
|
|
2019
Q1 | $29.9M | Buy |
319,923
+49,480
| +18% | +$4.62M | 0.23% | 140 |
|
|
2018
Q4 | $19.7M | Buy |
270,443
+99,588
| +58% | +$7.26M | 0.17% | 162 |
|
|
2018
Q3 | $15M | Sell |
170,855
-57,285
| -25% | -$5.01M | 0.11% | 189 |
|
|
2018
Q2 | $22.5M | Buy |
+228,140
| New | +$22.5M | 0.17% | 177 |
|
|
2016
Q4 | – | Sell |
-271,302
| Closed | -$18.4M | – | 259 |
|
|
2016
Q3 | $18.4M | Sell |
271,302
-5,465
| -2% | -$370K | 0.15% | 176 |
|
|
2016
Q2 | $15.4M | Buy |
+276,767
| New | +$15.4M | 0.13% | 185 |
|